Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) --
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
1 min read Premium comments
rotator cuffStryker Corporationsports medicineZuriMEDFiberLocker System
Stryker has completed its acquisition of ZuriMED, adding the FiberLocker System to its Sports Medicine portfolio
The acquisition adds a commercialized rotator cuff augmentation technology to Stryker’s shoulder portfolio
The addition expands Stryker’s ability to support shoulder specialists across sports medicine and shoulder care
Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and developer of the FiberLocker® System.
The FiberLocker System is a commercialized rotator cuff augmentation technology designed to increase the biomechanical strength of the repair. The differentiated technology addresses an important clinical need in rotator cuff repair and expands Stryker’s ability to support shoulder surgeons with innovative solutions across the shoulder continuum of care.
“ZuriMED brings specialized expertise and a differentiated technology that complements our growing shoulder care capabilities,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “Together, we have an opportunity to advance the FiberLocker technology, expand access to innovative treatment options and deliver greater value for our customers and their patients.”
About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries:
Nick Mead
Vice President, Investor Relations
nick.mead@stryker.com
For media inquiries:
Kim Montagnino
Vice President, Chief Communications Officer
kim.montagnino@stryker.com
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Stryker's acquisition of ZuriMED strategically enhances its Sports Medicine portfolio by integrating the commercialized FiberLocker System. This move expands Stryker's shoulder care capabilities, targeting an important clinical need in rotator cuff repair. The acquisition aims to advance the technology, broaden market access, and strengthen Stryker's competitive position by offering innovative solutions to shoulder specialists, driving value for customers and patients.
- The acquisition expands Stryker's market presence in shoulder care, leveraging a commercialized augmentation technology.
- This strategic integration supports Stryker's goal to offer a comprehensive portfolio and enhance its competitive edge in sports medicine.
PhD Lens: Clinical and outcomes impact
Stryker's acquisition of ZuriMED introduces the FiberLocker System, a commercialized rotator cuff augmentation technology. This system is specifically designed to increase the biomechanical strength of rotator cuff repairs, addressing a significant clinical need. The technology aims to provide innovative solutions for shoulder surgeons, enhancing repair integrity and potentially improving patient outcomes in rotator cuff procedures.
- The FiberLocker System functions as a rotator cuff augmentation technology, biomechanically strengthening repairs.
- It targets a clinical need by enhancing the integrity of rotator cuff repairs, though specific clinical evidence or material details are not provided.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.